CD19 and neoplasm: Unlike hematological malignancies with uniformly expressed and relatively cancer-specific antigen targets, such as CD19, the antigen heterogeneity and high mutation diversities between cells in solid tumors make it scarcely possible to find universal tumor antigens that are stably expressed on multiple tumor types or even on different cells within a single patient’s tumor [5–7].